REFERENCES
- Prescription drug monitoring programs: a brief overview. National Alliance for Model State Drug Laws (NAMSDL) Executive Summary, May 2012. Available at: http://www.namsdl.org/ presdrug.htm. Accessed July 16, 2012.
- Alliance of States with Prescription Monitoring Programs. PMP legislation and operational dates. Available at: http://www. pmpalliance.org/content/pmp-legislation-operational-dates? order=field_pmp_legis_enacted_value&sort=asc. Accessed Feb- ruary 2012.
- Gugelmann HM, Perrone J. Can prescription drug monitoring programs help limit opioid abuse? JAMA. 2011; 306:2258–2259.
- PMP Center of Excellence Notes from the Field, “Nevada's Proactive PMP: The impact of unsolicited reports,” 2011. Available at: http://www.pdmpexcellence.org/sites/all/pdfs/ nevada_nff_10_26_11.pdf. Accessed April 23, 2012.
- Blumenschein K, Fink JL, Freeman PR, Independent evaluation of the impact and effectiveness of the Kentucky All Schedule Prescription Electronic Reporting Program (KASPER). Available at: http://chfs.ky.gov/NR/rdonlyres/ 24493B2E-B1A1–4399-89AD1625953BAD43/0/KASPERE valuationFinalReport10152010.pdf. Accessed March 2012.
- PMP Center of Excellence, “Trends in Wyoming PMP prescription history reporting: evidence for a decrease in doctor shopping?” 2010. Available at: http://www.pmpexcellence.org/ sites/all/pdfs/NFF_wyoming_rev_11_16_10.pdf. Accessed April 23, 2012.
- GAO Report GAO-02-634: “Prescription drugs. State monitoring programs provide useful tool to reduce diversion,” 2002. Available at: http://www.gao.gov/new.items/d02634.pdf. Accessed April 23, 2012.
- National Association of Boards of Pharmacy. Available at: www.nabp.net. Accessed May 31, 2012.
- Manchikanti L, Fellows B, Allinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician. 2010;13:401–435.
- Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future: National Survey Results on Drug Use, 1975–2009: Volume 1: Secondary School Students. Bethesada, MD: National Institutes of Health; 2010. NIH Publication No. 10–7584.
- Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med. 2006;31:506–511.
- CDC grand rounds: prescription drug overdoses—a U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012;61:10–13.
- Unintentional drug poisoning in the United States. National Center for Injury Prevention and Control. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/ HomeandRecreationalSafety/pdf/poison-issue-brief.pdf. Accessed May 31, 2012.
- Martyres RF, Clede D, Burns JM. Seeking drugs or seeking help? Escalating “doctor shopping” by young heroin users before fatal overdose. Med J Aust. 2004;180:211–214.
- PMP Center of Excellence Notes from the Field, “Keeping Patients Safe: A Case Study on using Prescription Monitoring Program Data in an Outpatient Addictions Treatment Setting,” 2011. Available at: http://www.pdmpexcellence. org/sites/all/pdfs/methadone_treatment_nff_%203_2_11.pdf. Accessed Feb. 24, 2012.
- Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med. 2011;12:747–754.
- Kerlikowske G, Jones CM, Labelle RM, Prescription drug monitoring programs-lack of effectiveness or a call to action? Pain Med. 2011;12:687–689.
- Green TC, Zaller N, Rich J, Revisiting Paulozzi et al.'s Prescription drug monitoring programs and death rates from drug overdose. Pain Med. 2011;12:982–985.
- Reifler LM, Droz D, Bailey JE, Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012;13:434–442.
- Chou R, Fanciullo GJ, Fine PG, American Pain Society–American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10: 113–130.
- PMP Center of Excellence Briefing on PMP Effectiveness, “Prescription Monitoring Programs: An effective tool in curbing the prescription drug abuse epidemic,” 2012. Available at: http://www.pdmpexcellence.org/sites/all/pdfs/pmp_effectiveness_ brief_revised_3_29_12.pdf. Accessed May 31, 2012.
- Katz N, Panas L, Kim M, Usefulness of prescription monitoring programs for surveillance—analysis of Schedule II opioid prescription data in Massachusetts, 1996–2006. Pharmacoepidemiol Drug Saf. 2010;19:115–123.
- Baehren DF, Marco CA, Droz DE, A state-wide prescription monitoring program affects emergency department prescribing behaviors. Ann Emerg Med. 2010;56:19–23.
- Gourlay DL, Heit HA, Almahrezi A. Universal preautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6:107–112.
- Weaver MF, Schnoll SH. Risk assessment for opioid misuse in chronic pain treatment. Adv Pain Manage. 2008;2:68–75.
- Weaver MF, Schnoll SH. Opioid treatment of chronic pain in patients with addiction. J Pain Palliat Care Pharmacother. 2002;16:5–26.
- Weaver MF, Schnoll SH. Addiction issues in prescribing opioids for chronic nonmalignant pain. J Addict Med. 2007;1:2–10.
- Weaver MF. Prescribing medications with potential for abuse. J Clin Outcomes Manage. 2009;16:171–179.
- Alliance of States with Prescription Monitoring Programs. Who is authorized to request patient prescription data. 2011. Available at: http://www.pmpalliance.org/content/who-authorized-requestpatient-prescription-data. Accessed May 24, 2012.